Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
November 9, 2025JAMA

SGLT2 Inhibitors and Kidney Outcomes by Glomerular Filtration Rate and Albuminuria

View Full Paper
Ask AI
Bookmark
Share

Authors

BNBrendon L. NeuenRFRobert A. FletcherSAStefan D. Anker

Discussion

Loading...

Member takes

Overview

Meta-analysis shows SGLT2 inhibitors reduce kidney failure in chronic kidney disease, indicating improved outcomes for type 2 diabetes patients.

Key Points

  • SGLT2 inhibitors reduced the risk of kidney failure, with HR of 0.66 across various eGFR categories.
  • The analysis included 70,361 participants from 10 randomized trials evaluating treatment effects.
  • A consistent reduction in annual eGFR decline was observed in chronic kidney disease patients.
  • Results may support routine use of SGLT2 inhibitors for kidney health improvement in diabetes patients.

Cite This Study

Neuen et al. (2025) studied this question.

synapsesocial.com/papers/690fdcdaf60c54d04ea37fa4https://doi.org/10.1001/jama.2025.20834
View Full Paper
Ask AI
Bookmark
Share